Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Share:
Related
Heavy News Day For Several Biotech Stocks
Catalysts AbbVie Investors Need To Watch

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

DateFirmActionFromTo
Feb 2015CitigroupInitiates Coverage onSell
Feb 2015JefferiesMaintainsBuy
Jan 2015BarclaysMaintainsOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→